Actively Recruiting

Age: 12Years +
All Genders
NCT06694363

New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome

Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-03-23

14

Participants Needed

7

Research Sites

235 weeks

Total Duration

On this page

Sponsors

A

Assistance Publique - Hôpitaux de Paris

Lead Sponsor

U

URC-CIC Paris Descartes Necker Cochin

Collaborating Sponsor

AI-Summary

What this Trial Is About

The study would like to compare patient samples at different time points using state-of the art-phenotyping tools. Collection of blood samples of APDS patients undergoing PI3K inhibitor treatment will be collected when feasible according to the standard of care planning (a blood test is supposed to be performed for these patients at M0-M3-M6-M12 then each 6 months for a total period of 2 years from the beginning of the PI3K inhibitor treatment). The whole blood will be processed in order to isolate the peripheral blood mononuclear cells (PBMC) and the plasma. Serum, RNA and DNA extraction will be performed on a separate sample.

CONDITIONS

Official Title

New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome

Who Can Participate

Age: 12Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with genetic diagnosis of APDS type 1 or type 2 planned for PI3Kδ selective inhibitor leniolisib treatment
  • Primary immunodeficient patients with new disease-causing variants in PIK3CD or PIK3R1 genes
  • Minimum age 12 years old
  • Patients or their guardians do not oppose participation
  • Patients affiliated with a health insurance scheme or beneficiaries
  • Patients with genetic diagnosis of APDS type 1 or type 2 already treated with leniolisib in the last 2 years
  • Patients with available pre-treatment samples
Not Eligible

You will not qualify if you...

  • Previous bone marrow transplantation
  • Refusal to participate in the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

Hôpital Haut Levêque - BORDEAUX

Bordeaux, France, 33000

Not Yet Recruiting

2

Hôpital Pellerin Enfants - BORDEAUX

Bordeaux, France, 33000

Not Yet Recruiting

3

Hôpital Jeanne de Flandres - LILLE

Lille, France, 59000

Actively Recruiting

4

Hôpital La Timone adulte - MARSEILLE

Marseille, France, 13000

Not Yet Recruiting

5

Hôpital Necker Enfants Malades - PARIS

Paris, France, 75015

Actively Recruiting

6

CHU IUCT Oncopole - TOULOUSE

Toulouse, France

Not Yet Recruiting

7

Hôpital des enfants - TOULOUSE

Toulouse, France

Not Yet Recruiting

Loading map...

Research Team

M

Michaela SEMERARO, MD, PhD

CONTACT

L

Laure CHOUPEAUX, MSc

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here